| Title |
Anthracycline Chemotherapy and Cardiotoxicity
|
|---|---|
| Published in |
Cardiovascular Drugs and Therapy, February 2017
|
| DOI | 10.1007/s10557-016-6711-0 |
| Pubmed ID | |
| Authors |
John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon |
| Abstract |
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon. Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 40% |
| United States | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 954 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 954 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 149 | 16% |
| Student > Master | 113 | 12% |
| Student > Ph. D. Student | 106 | 11% |
| Researcher | 85 | 9% |
| Student > Doctoral Student | 54 | 6% |
| Other | 142 | 15% |
| Unknown | 305 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 216 | 23% |
| Biochemistry, Genetics and Molecular Biology | 128 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 90 | 9% |
| Chemistry | 45 | 5% |
| Agricultural and Biological Sciences | 31 | 3% |
| Other | 108 | 11% |
| Unknown | 336 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 218. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2023.
All research outputs
#178,165
of 25,490,562 outputs
Outputs from Cardiovascular Drugs and Therapy
#4
of 771 outputs
Outputs of similar age
#3,970
of 425,178 outputs
Outputs of similar age from Cardiovascular Drugs and Therapy
#2
of 7 outputs
Altmetric has tracked 25,490,562 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 771 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,178 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.